Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF2R | P11717 | 4/20 | 0.62 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.51 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.51 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | TYR | P14679 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12191970 | 1.00 | IGF2R (0.62) | IGF2RGAALGALS8LGALS3LGALS4 | |
| SCHEMBL15489111 | 1.00 | IGF2R (0.62) | IGF2RGAALGALS8LGALS3LGALS4 | |
| SCHEMBL5311408 | 1.00 | IGF2R (0.62) | IGF2RGAALGALS8LGALS3LGALS4 | |
| SCHEMBL15489112 | 1.00 | IGF2R (0.62) | IGF2RGAALGALS8LGALS3LGALS4 | |
| SCHEMBL6685329 | 1.00 | IGF2R (0.62) | IGF2RGAALGALS8LGALS3LGALS4 | |
| SCHEMBL24696627 | 1.00 | IGF2R (0.62) | IGF2RGAALGALS8LGALS3LGALS4 | |
| SCHEMBL13818478 | 1.00 | IGF2R (0.62) | IGF2RGAALGALS8LGALS3LGALS4 | |
| SCHEMBL5316339 | 1.00 | IGF2R (0.62) | IGF2RGAALGALS8LGALS3LGALS4 | |
| SCHEMBL13818477 | 1.00 | IGF2R (0.62) | IGF2RGAALGALS8LGALS3LGALS4 | |
| SCHEMBL13713744 | 1.00 | IGF2R (0.62) | IGF2RGAALGALS8LGALS3LGALS4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 119 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260021190-A1 | GLUCOSE-RESPONSIVE INSULIN CONJUGATES COMPRISING A PENTA-VALENT SUGAR CLUSTER FOR TREATMENT OF DIABETES | MERCK SHARP & DOHME LLC (US) | 2026-01-22 | — | — | US | disclosed |
| EP-4615487-A1 | GLUCOSE-RESPONSIVE INSULIN CONJUGATES COMPRISING A PENTA-VALENT SUGAR CLUSTER FOR TREATMENT OF DIABETES | Merck Sharp & Dohme LLC (US) | 2025-09-17 | — | — | EP | disclosed |
| US-20250127887-A1 | Self-Assembling Nanoparticles Based On Amphiphilic Peptides | BARINTHUS BIOTHERAPEUTICS NORTH AMERICA, INC. (US) | 2025-04-24 | — | — | US | disclosed |
| EP-4436610-A1 | GLUCOSE-RESPONSIVE INSULIN CONJUGATES COMPRISING A TETRA-VALENT SUGAR CLUSTER FOR TREATMENT OF DIABETES | Merck Sharp & Dohme LLC (US) | 2024-10-02 | — | — | EP | disclosed |
| WO-2024102633-A1 | GLUCOSE-RESPONSIVE INSULIN CONJUGATES COMPRISING A PENTA-VALENT SUGAR CLUSTER FOR TREATMENT OF DIABETES | MERCK SHARP & DOHME LLC (US) | 2024-05-16 | — | — | WO | disclosed |
| EP-4294431-A1 | SELF-ASSEMBLING NANOPARTICLES BASED ON AMPHIPHILIC PEPTIDES | Vaccitech North America, Inc. (US) | 2023-12-27 | — | — | EP | disclosed |
| US-11820805-B2 | Conjugate based systems for controlled insulin delivery | MERCK SHARP & DOHME LLC (US) | 2023-11-21 | — | — | US | disclosed |
| US-11820805-B2 | Conjugate based systems for controlled insulin delivery | MERCK SHARP & DOHME LLC (US) | 2023-11-21 | — | — | US | disclosed |
| US-11820805-B2 | Conjugate based systems for controlled insulin delivery | MERCK SHARP & DOHME LLC (US) | 2023-11-21 | — | — | US | disclosed |
| WO-2023091441-A1 | GLUCOSE-RESPONSIVE INSULIN CONJUGATES COMPRISING A TETRA-VALENT SUGAR CLUSTER FOR TREATMENT OF DIABETES | MERCK SHARP & DOHME LLC (US) | 2023-05-25 | — | — | WO | disclosed |
| WO-2010088276-A2 | POLYNUCLEOTIDE APTAMER-BASED CROSS -LINKED MATERIALS AND USES THEREOF | SMARTCELLS, INC. (US) | 2010-08-05 | — | — | WO | disclosed |
| WO-2010088286-A1 | SYNTHETIC CONJUGATES AND USES THEREOF | SMARTCELLS, INC. (US) | 2010-08-05 | — | — | WO | disclosed |
| WO-2010088261-A1 | BINDING-SITE MODIFIED LECTINS AND USES THEREOF | SMARTCELLS, INC. (US) | 2010-08-05 | — | — | WO | disclosed |
| WO-2010088300-A1 | CRYSTALLINE INSULIN-CONJUGATES | SMARTCELLS, INC. (US) | 2010-08-05 | — | — | WO | disclosed |
| EP-1200484-A4 | METHODS AND REAGENTS MAKING MULTIVALENT ARRAYS AND COMBINATORIAL LIBRARIES OF MULTIVALENT ARRAYS | WISCONSIN ALUMNI RES FOUND (US) | 2005-07-06 | — | — | EP | disclosed |
| WO-2004067732-A2 | POLYMER CARRIERS WITH BONDED SACCHARIDES FOR IMMOBILIZATION OF BIOLOGICAL SYSTEMS | ÚSTAV MAKROMOLEKULÁRNÍ CHEMIE AKADEMIE VEDCESKÉ REPUBLIKY (CZ) | 2004-08-12 | — | — | WO | disclosed |
| US-6538072-B2 | Polymerizing monomer comprising polymerizable group and at least one latent reactive group in the presence of a metal carbene catalyst to form a polymer template comprising at least one latent reactive group | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2003-03-25 | — | — | US | disclosed |
| EP-1200484-A1 | METHODS AND REAGENTS MAKING MULTIVALENT ARRAYS AND COMBINATORIAL LIBRARIES OF MULTIVALENT ARRAYS | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2002-05-02 | — | — | EP | disclosed |
| US-6271315-B1 | FORMING A POLYMER IN THE PRESENCE OF METAL CARBENE CATALYST TO FORM TEMPLATE | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2001-08-07 | — | — | US | disclosed |
| WO-2000078821-A1 | METHODS AND REAGENTS MAKING MULTIVALENT ARRAYS AND COMBINATORIAL LIBRARIES OF MULTIVALENT ARRAYS | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2000-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250127887-A1 | Self-Assembling Nanoparticles Based On Amphiphilic Peptides | IAPP, BRCA1, ANXA11 | IGF2R 4034/4885GAA 1636/4885LGALS8 1742/4885 |
| US-11820805-B2 | Conjugate based systems for controlled insulin delivery | GPR119, INSR, IGF1R | IGF2R 38/4885GAA 987/4885LGALS8 680/4885 |
| US-20260021190-A1 | GLUCOSE-RESPONSIVE INSULIN CONJUGATES COMPRISING A PENTA-VALENT SUGAR CLUSTER FOR TREATMENT OF DIABETES | INSR, GPR119, GLP1R | IGF2R 5/4885GAA 83/4885LGALS8 615/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.